Abstract SY45-04: Development of therapeutic strategies by resolving the tumor ecosystem
Benjamin Izar(Columbia University Irving Medical Center), Aviv Regev(Broad Institute), Genevieve M. Boland(Harvard University), Parin Shah(Harvard University), Charles H. Yoon(Brigham and Women's Hospital), Abhay Kanodia(Dana-Farber Cancer Institute), E.M. Van Allen(Dana-Farber Cancer Institute), Kai W. Wucherpfennig(Dana-Farber Cancer Institute), Dirk Schadendorf(National Center for Tumor Diseases), Asaf Rotem(AstraZeneca (South Korea)), Johannes C. Melms(Columbia University Irving Medical Center), Rachel Leeson(Dana-Farber Cancer Institute), Michael C. Cuoco(Broad Institute), Jia‐Ren Lin(Harvard University), Levi A. Garraway(Broad Institute), Peter K. Sorger(Harvard University Press), Orit Rozenblatt–Rosen(Broad Institute), Livnat Jerby‐Arnon(Broad Institute), Gao Zhang(Central South University), F. Stephen Hodi(Harvard University), Itay Tirosh(Weizmann Institute of Science), Mei-Ju Su(Harvard University), Christopher Rodman(Broad Institute)
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k